Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management

Pneumonia

Anolin Aslan¹  Naime Majidi Zolbanin²  Cynthia Aslan³  Reza Jafari⁴ 

[1] Department of Critical Care Nursing, School of Nursing and Midwifery, Tehran University of Medical Science, Tehran, Iran;Experimental and Applied Pharmaceutical Research Center, Urmia University of Medical Sciences, Urmia, Iran;Department of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran;Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran;Nephrology and Kidney Transplant Research Center, Clinical Research Institute, Urmia University of Medical Sciences, P.O. Box: 1138, Shafa St., Ershad Blvd., 57147, Urmia, Iran;Hematology, Immune Cell Therapy, and Stem Cell Transplantation Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran;

关键词: COVID-19;    Acute respiratory distress syndrome;    SARS-CoV-2;    Pandemics;    ARDS;   

DOI  :  10.1186/s41479-021-00092-9

来源: Springer

【 摘 要 】

COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even though COVID-19 vaccinations are available now, there is still an urgent need to find potential treatments to ease the effects of COVID-19 on already sick patients. Multiple experimental drugs have been approved by the FDA with unknown efficacy and possible adverse effects. Probably the increasing number of studies worldwide examining the potential COVID-19 related therapies will help to identification of effective ARDS treatment. In this review article, we first provide a summary on immunopathology of ARDS next we will give an overview of management of patients with COVID-19 requiring intensive care unit (ICU), while focusing on the current treatment strategies being evaluated in the clinical trials in COVID-19-induced ARDS patients.

【 授权许可】

CC BY